Latest News, Grants & Research Reports
Read our latest news, blog posts and research updates right here
From molecules to medicine: new funding to accelerate rare childhood cancer research
Thanks to your kind donations, Neuroblastoma UK is pleased to announce two research grant awards totalling £683,477, with a focus on improving treatment for children with advanced stages of the disease.
The grants, which include a donation of £15,000 from charity Friends of Rosie, will enable scientists to progress their research and develop safer, non-invasive and more effective treatment for children with the disease.
Research Q&A with Professor Deb Tweddle
During Childhood Cancer Awareness Month 2021, we invited our supporters to share their neuroblastoma research questions with us.
Professor Deb Tweddle, Professor of Paediatric Oncology at Newcastle University and an Honorary Consultant in Paediatric and Adolescent Oncology at the Great North Children’s Hospital, Newcastle answers questions about research into neuroblastoma relapse, survival and treatment options.
A step towards better precision in treatment
A new international risk classification system has been developed for children with neuroblastoma in North America, with further revisions that could benefit children with the disease around the world.
Clinical trial for children with high-risk neuroblastoma open
We are delighted to share that the SIOPEN High-Risk Neuroblastoma 2 trial is now officially open and ready to recruit at its first UK hospital, with more to follow soon.
In May 2020, we announced the award of £609, 762 in partnership with Solving Kids Cancer to open the UK sites of the SIOPEN High-Risk Neuroblastoma 2 trial. This latest European-wide study will look to answer important questions about the standard care protocols for children with high-risk neuroblastoma, and how they might be improved.
Neuroblastoma UK announces new 2021 Grant Round
We are delighted to announce the launch of our new research Grant Round for 2021.
Postponed from 2020 due to the coronavirus pandemic, our biennial grant round for 2021 will focus on applications for research that will have the greatest potential impact to improve treatment for children with neuroblastoma.
Developing personalised treatment for ALK-positive neuroblastoma
Thanks to funding from Neuroblastoma UK, post-doctoral research associate Dr Perla Pucci was recruited to join a neuroblastoma research team at the University of Cambridge.
The team, led by Dr Suzanne Turner, are looking to develop more personalised treatment for children with ALK-positive neuroblastoma. Perla tells us more about how the project has progressed.
New immunotherapy shows promise for treating neuroblastoma
A novel CAR T-cell therapy designed to target cancerous tumours has shown promising early results in treating children with neuroblastoma.
The original pre-clinical work was funded by Neuroblastoma UK to help launch the study. Dr Karin Straathof, one of the lead investigators on the study, tells us more.
Understanding potential cancer-causing proteins to improve neuroblastoma treatment
In 2019, Neuroblastoma UK provided a grant of £143,648 to Dr Andrew Stoker and his team at University College London.
The team want to investigate how a particular protein that is well known to promote tumours in several cancers including breast, lung and prostate cancer works in neuroblastoma cells.
A potential new treatment for neuroblastoma
We welcome the news that a potential new treatment for children with neuroblastoma will be advanced to clinical trial and reach more young cancer patients.
Researchers have found an indirect way to target N-Myc, a gene that occurs in aggressive forms of neuroblastoma. They found that a new drug, fadraciclib, is effective at blocking N-Myc activity by switching off the production of N-Myc and a clinical trial for children with high-risk neuroblastoma is due to open by the end of 2020.
September Research News
Read the latest neuroblastoma news from September.
New insights into neuroblastoma could help better tailor treatment for children affected by this rare and aggressive cancer.